SCHEMBL3463152

SCHEMBL3463152

COc1ncc(/C(N)=N/O)cc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.41
LMNA P02545 2/20 0.40
GFER P55789 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GAA P10253 4/20 0.35
NNMT P40261 2/20 0.35
RAB9A P51151 2/20 0.35
POLB P06746 1/20 0.34
MAPT P10636 3/20 0.33
PIK3R1 P27986 1/20 0.33
PIK3CA P42336 1/20 0.33
MTOR P42345 1/20 0.33
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33
ALOX15 P16050 1/20 0.33
HSD17B10 Q99714 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32
CASP1 P29466 1/20 0.32
HPGDS O60760 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3463153 1.00 RECQL (0.41) RECQLLMNAGFERKMT2AL3MBTL1
SCHEMBL25241798 0.79 LMNA (0.40) RECQLLMNAGFERKMT2AL3MBTL1
SCHEMBL29392876 0.79 LMNA (0.40) RECQLLMNAGFERKMT2AL3MBTL1
SCHEMBL1727070 0.77 NOS3 (0.48) RECQLLMNAGFERKMT2AL3MBTL1
SCHEMBL1727072 0.77 NOS3 (0.48) RECQLLMNAGFERKMT2AL3MBTL1
SCHEMBL29393259 0.77 LMNA (0.36) RECQLLMNAGFERKMT2AL3MBTL1
SCHEMBL25231695 0.77 LMNA (0.36) RECQLLMNAGFERKMT2AL3MBTL1
SCHEMBL20116736 0.75 GAA (0.44) RECQLLMNAKMT2AGAARAB9A
SCHEMBL3430654 0.74 HCAR2 (0.44) L3MBTL1MAPTALOX15HSD17B10
SCHEMBL27248266 0.74 PIK3R1 (0.32) RECQLNNMTPOLBMAPTPIK3R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE ALMIRALL S.A. (ES) 2011-12-22 US disclosed
EP-2202232-A1 1,2,4-oxadiazole derivatives and their therapeutic use Laboratorios Almirall, S.A. (ES) 2010-06-30 EP disclosed
EP-2202232-A1 1,2,4-oxadiazole derivatives and their therapeutic use Laboratorios Almirall, S.A. (ES) 2010-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110311485-A1 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE S1PR1, S1PR2, S1PR3 RECQL 4104/4885LMNA 3702/4885GFER 4451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.